StageZero Life Sciences Ltd (TSE:SZLS) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
StageZero Life Sciences has reported increased revenues in the third quarter of 2024, following operational improvements including a 70% cost reduction from lab relocation and an expanded CareOncology presence in Europe. The company is focusing on strategic partnerships to boost the uptake of its multi-cancer diagnostic test, Aristotle, anticipating further revenue growth.
For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.